Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant...
549 74, 424 9, A61K 4902, C07D33312
Radiopharmaceuticals useful in brain imaging comprising radiohalogenated thienylethylamine derivatives. The compounds are 5-halo-thiophene-2-isopropyl amines able to cross the blood-brain barrier and be retained for a sufficient length of time to allow the evaluation or regional blood flow by radioimaging of the brain.
patent: 2367702 (1945-01-01), Van Zoeren
patent: 4360511 (1982-11-01), Baldwin et al.
patent: 4458086 (1984-07-01), Chekroun et al.
patent: 4482718 (1984-11-01), Chekroun et al.
Fernandez-Tome, et al., "Relation Between Locomotor Hyperactivity Induced by P-Chloroamphetamine in Rats and Uptake of .sup.3 H-Dopamine," Arch, Farmacol Toxicol 1979, 5(3), 169-171.
David E. Kuhl et al., "Quantifying Local Cerebral Blood Flow by N-Isopropyl-p-Iodamphetamine (IMP) Tomography," Oct. 15, 1981, pp. 196-203.
Hank F. Kung, et al., "A New Brain Perfusion Imaging Agent:[1-123]HIPDM:N,N,N'-Trimethyl-N'-[2-Hydroxy-3-Methyl-5-Iodobenzyl]-1 ,3-Propanediamine," Jun. 3, 1982, pp. 66-72.
Goodman Mark M.
Knapp, Jr. Furn F.
Hamel Stephen D.
Lovingood Katherine P.
Maples John S.
Moser William R.
The United States of America as represented by the United States
Radiohalogenated thienylethylamine derivatives for evaluating lo does not yet have a rating. At this time, there are no reviews or comments for this patent.If you have personal experience with Radiohalogenated thienylethylamine derivatives for evaluating lo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiohalogenated thienylethylamine derivatives for evaluating lo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1166622